. 2022 Mar 17;11(6):1666. doi: 10.3390/jcm11061666

Table 1.

Characteristics of included studies.

First Author (Year)	Tendon Investigated	Study Groups	Sample Size (n)	Type of Population	Mean Age (Years; Mean ± SD)	Intervention Duration (Weeks)	Symptom Duration (Months)	Time Points of Measurement
Balius et al. (2016)	Achilles tendon (mid-portion)	MCVC + EC	17	non-athletic	43.5 ± 14.5	12	>3	baseline, 6 and 12 w
Balius et al. (2016)	Achilles tendon (mid-portion)	EC	20	non-athletic	38.9 ± 6.6	12	>3	baseline, 6 and 12 w
Juhasz et al. (2018)	Musculus flexor hallucis longus	Creatine	9	athletic	15.5 ± 1.4	6	1–1.5	2, 4 and 6 w
Juhasz et al. (2018)	Musculus flexor hallucis longus	Placebo	9	athletic	14.8 ± 1.6	6	1–1.5	2, 4 and 6 w
Mavrogenis et al. (2004)	Patellar & several upper body tendons *	EFA, AO and US	17	athletic	31	5	>3	8, 16, 24 and 32 d
Mavrogenis et al. (2004)	Patellar & several upper body tendons *	Placebo and US	14	athletic	32	5	>3	8, 16, 24 and 32 d
Notarnicola et al. (2012)	Achilles tendon (insertional)	ESWT and tenosan	32	non-athletic	55.8 ± 13.2	8	>6	2 and 6 m
Notarnicola et al. (2012)	Achilles tendon (insertional)	ESWT and placebo	32	non-athletic	55.8 ± 13.2	8	>6	2 and 6 m
Praet et al. (2019)	Achilles tendon (mid-portion)	TENDOFORTE + EccEx	10	non-athletic	45.3 ± 6.4	12	18	3 and 6 m
Praet et al. (2019)	Achilles tendon (mid-portion)	Placebo + EccEx	10	non-athletic	42.0 ± 9.4	12	18	3 and 6 m
Sandford et al. (2018)	Rotator cuff	PUFAs	38	non-athletic	52.2 ± 12.0	8	>3	8 w, 3, 6 and 12 m
Sandford et al. (2018)	Rotator cuff	Placebo	35	non-athletic	52.0 ± 16.2	8	>3	8 w, 3, 6 and 12 m

d, days; m, months; w, weeks; AO, antioxidants; EC/EccEx, eccentric exercise; EFA, essential fatty acids; ESWT, extracorporeal shockwave therapy; MCVC, mucopolisaccharides, type I collagen, and vitamin C; PUFAs, polyunsaturated fatty acids; US, ultrasound; *, upper body tendons: supraspinatus, biceps, lateral epicondyle extensormedial epicondyle flexor, and infraspinatus.